Literature DB >> 33855715

Metachromatic leukodystrophy: A single-center longitudinal study of 45 patients.

Francesca Fumagalli1,2,3, Alberto A Zambon3,4, Paola M V Rancoita5, Cristina Baldoli6, Sabrina Canale1,7, Ivana Spiga8, Stefania Medaglini3, Rachele Penati4,9, Marcella Facchini1, Francesca Ciotti2, Marina Sarzana2, Laura Lorioli2, Martina Cesani1,10, Maria Grazia Natali Sora3, Ubaldo Del Carro3, Federica Cugnata5, Gigliola Antonioli2, Salvatore Recupero2,4, Valeria Calbi1,2, Clelia Di Serio5, Alessandro Aiuti1,2,4, Alessandra Biffi1,11, Maria Sessa1,12.   

Abstract

In this study, we characterize the natural course of metachromatic leukodystrophy (MLD), explore intra/inter group differences, and identify biomarkers to monitor disease progression. This is a longitudinal observational study. Genotype and characteristics at disease onset were recorded. Time-to-event analyses were performed to assess time to major disease-related milestones in different subgroups. Longitudinal trajectories of nerve conduction velocities (NCV), brain MRI score, and brainstem auditory evoked responses (BAERs) were described. We recruited 22 late-infantile, 14 early-juvenile, 5 late-juvenile, and 4 adult MLD patients. Thirty-four were prospectively evaluated (median FU time 43 months). In late-infantile patients, the attainment of independent walking was associated with a later age at dysphagia. In early-juvenile, the presence of isolated cognitive impairment at onset was not a favorable prognostic factor. Late-infantile and early-juvenile subjects showed similar rapid loss of ambulation and onset of seizures, but late-infantile displayed earlier loss of trunk control, dysphagia, and death. We found significant differences in all major disease-related milestones (except death) between early-juvenile and late-juvenile patients. Late-juvenile and adult patients both presented with a predominant cognitive impairment, mild/no peripheral neuropathy, lower brain MRI score at plateau compared to LI/EJ, and later cerebellar involvement. NCV and BAER were consistently severely abnormal in late-infantile but not in older subjects, in whom both NCV and BAER were variably affected, with no deterioration over time in some cases. This study clarifies intra/inter group differences between MLD subtypes and provides additional indications regarding reliable clinical and instrumental tools to monitor disease progression and to serve as areference to evaluate the efficacy of future therapeutic interventions inthe different MLD variants.
© 2021 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Entities:  

Keywords:  MLD; longitudinal study; metachromatic leukodystrophy; natural history

Mesh:

Year:  2021        PMID: 33855715     DOI: 10.1002/jimd.12388

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  3 in total

1.  Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi).

Authors:  Daphne H Schoenmakers; Shanice Beerepoot; Sibren van den Berg; Laura Adang; Annette Bley; Jaap-Jan Boelens; Francesca Fumagalli; Wim G Goettsch; Sabine Grønborg; Samuel Groeschel; Peter M van Hasselt; Carla E M Hollak; Caroline Lindemans; Fanny Mochel; Peter G M Mol; Caroline Sevin; Ayelet Zerem; Ludger Schöls; Nicole I Wolf
Journal:  Orphanet J Rare Dis       Date:  2022-02-14       Impact factor: 4.123

2.  Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy.

Authors:  F Eichler; Caroline Sevin; M Barth; F Pang; K Howie; M Walz; A Wilds; C Calcagni; C Chanson; L Campbell
Journal:  Orphanet J Rare Dis       Date:  2022-10-04       Impact factor: 4.303

3.  Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.

Authors:  Francesca Fumagalli; Valeria Calbi; Maria Grazia Natali Sora; Maria Sessa; Cristina Baldoli; Paola Maria V Rancoita; Francesca Ciotti; Marina Sarzana; Maddalena Fraschini; Alberto Andrea Zambon; Serena Acquati; Daniela Redaelli; Vanessa Attanasio; Simona Miglietta; Fabiola De Mattia; Federica Barzaghi; Francesca Ferrua; Maddalena Migliavacca; Francesca Tucci; Vera Gallo; Ubaldo Del Carro; Sabrina Canale; Ivana Spiga; Laura Lorioli; Salvatore Recupero; Elena Sophia Fratini; Francesco Morena; Paolo Silvani; Maria Rosa Calvi; Marcella Facchini; Sara Locatelli; Ambra Corti; Stefano Zancan; Gigliola Antonioli; Giada Farinelli; Michela Gabaldo; Jesus Garcia-Segovia; Laetitia C Schwab; Gerald F Downey; Massimo Filippi; Maria Pia Cicalese; Sabata Martino; Clelia Di Serio; Fabio Ciceri; Maria Ester Bernardo; Luigi Naldini; Alessandra Biffi; Alessandro Aiuti
Journal:  Lancet       Date:  2022-01-22       Impact factor: 79.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.